LUT014 0.1% Gel Demonstrated Statistically Significant Improvement in Treatment Success Achieved by 71.8% of Patients …
PR Newswire
© Israel Daily | All Rights Reserved
Latest in PR Newswire
-
-
PR Newswire
China (Guangzhou) International Building Decoration Fair Looks Ahead to 2027 with Expanded Global Connections
GUANGZHOU, China, Sept. 30, 2026 /PRNewswire/ — The 2026 China (Guangzhou) International Building Decoration Fair …
-
PR Newswire
Arasan to demonstrate the industry’s first MIPI SWI3S™ IP at the MIPI Member meet in Taipei
Arasan Chip Systems, announces that it will demonstrate the industries first MIPI SWI3S™ Manager IP …
-
PR Newswire
Airway Therapeutics Awarded $1.9 Million NIH Grant to Advance Phase 2b/3 Study of Zelpultide Alfa for Prevention of Bronchopulmonary Dysplasia
NIH funding provides non-dilutive capital to advance late-stage U.S. clinical development of zelpultide alfa Program …
-
PR Newswire
China (Guangzhou) International Building Decoration Fair Looks Ahead to 2027 with Expanded Global Connections
GUANGZHOU, China, Sept. 29, 2026 /PRNewswire/ — The 2026 China (Guangzhou) International Building Decoration Fair …
-
PR Newswire
Cellebrite Calls for 2027 JUSTYS Nominees, Premier Event Highlights Unsung Heroes Who Keep the World Safe
Law&Crime Network and NewsNation anchor Jesse Weber returns to host; ceremony to stream live to …
-
PR Newswire
Jiahui Health Highlights China’s Growing Role in Global Medical Tourism at WTO Public Forum 2026
GENEVA, Sept. 18, 2026 /PRNewswire/ — China is seeing growing momentum in inbound medical tourism, …
-
PR Newswire
Cellebrite Expands Global Digital Community, ‘The 101’, for Digital Forensics and Investigative Professionals
Purpose-built platform connects customers worldwide with peers and Cellebrite experts into an always-on community TYSONS …
-
BEIJING, Sept. 17, 2026 /PRNewswire/ — Following the successful conclusion of the UIPM 2026 Obstacle …
-
PR Newswire
Lutris Pharma to Present Updated Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the EADV Congress
TEL AVIV, Israel, Sept. 16, 2026 /PRNewswire/ — Lutris Pharma, a clinical stage biopharmaceutical company …
Newer Posts